Disease Landscape and Forecast 인사이트

Clarivate Epidemiology’s coverage of acute coronary syndrome (ACS) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Obesity is a significant public health concern. Although inexpensive phentermine is commonly prescribed for weight management, newer therapies like glucagon-like peptide-1 (GLP-1) receptor agonists…

Clarivate Epidemiology’s coverage of postoperative pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of acute coronary syndrome (ACS) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key acute coronary syndrome patient populations covering 171 countries…

Clarivate Epidemiology’s coverage of ACS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence of ACS for each…

Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and…

In 2022, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $150 billion in the major pharmaceutical markets under…

In 2022, sales of branded biologics in ophthalmology exceeded $9.8 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast period…

In 2022, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $136 billion in the major pharmaceutical markets under study (United…

In 2022, sales of branded biologics for respiratory indications totaled about $2.3 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032…

In 2022, sales of insulins at the ex-manufacturer price level exceeded $16 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast…